今天3分钟我们来聊聊胶质母细胞瘤耐药免疫疗法DRI新突破源于细胞BioInsid的个人播客

今天3分钟我们来聊聊胶质母细胞瘤耐药免疫疗法DRI新突破

8分钟 ·
播放数4
·
评论数0

胶质母细胞瘤是恶性脑肿瘤,20年无新药,中位生存期仅11个月。IN8bio公司研发DRI疗法,给γδ T细胞插入MGMT基因,使其对化疗药替莫唑胺耐药,能在化疗中存活。化疗让肿瘤亮应激信号灯,γδ T细胞可识别杀伤。临床试验中重复给药组PFS翻倍,安全性好,2期试验已启动,未来或成治疗新方向。

本期参考文献:

  1. Nabors LB, Lobbous M, Han X, et al. Intracranial Injection of Investigational Ex Vivo Expanded and Activated Gamma-Delta T Cells Engineered With a Methylguanine-DNA Methyltransferase–Expressing Lentivector in Patients With Primary Glioblastoma. J Clin Oncol. 2026 Jul 8. DOI: 10.1200/JCO-25-02463. ascopubs.org

  2. IN8bio Announces Publication in The Journal of Clinical Oncology Demonstrating DeltEx™ DRI Doubles Progression-Free Survival in Newly Diagnosed Glioblastoma [新闻稿]. 2026-07-09. investors.in8bio.com

  3. Nabors LB, et al. INB-200: Phase I study and characterization of gene-modified autologous gamma delta (γδ) T cells in newly diagnosed glioblastoma multiforme (GBM). J Clin Oncol 44, 2077 (2026). 2026 ASCO Annual Meeting. DOI: 10.1200/JCO.2026.44.16_suppl.2077

  4. Lamb LS Jr, et al. Engineered Drug Resistant γδ T Cells Kill Glioblastoma Cell Lines during a Chemotherapy Challenge: A Strategy for Combining Chemo- and Immunotherapy. PLoS ONE. 2013. pmc.ncbi.nlm.nih.gov

  5. Lamb LS Jr, et al. A combined treatment regimen of MGMT-modified γδ T cells and temozolomide chemotherapy is effective against primary high grade gliomas. Clin Cancer Res. 2021. pmc.ncbi.nlm.nih.gov